3.83Open3.83Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover732.92%IV-23.55%PremiumSep 20, 2024Expiry Date4.05Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4699Delta0.2235Gamma0.22Leverage Ratio-0.0143Theta-0.0021Rho-0.10Eff Leverage0.0010Vega
Neuronetics Stock Discussion
Neuronetics and Greenbrook TMS Announce Definitive Agreement to Merge
Neuronetics (NASDAQ: STIM) and Greenbrook TMS (OTCMKTS: GBNHF) have announced a definitive agreement to merge in an all-stock transaction. The merger aims to create a vertically-integrated organization providing TMS therapy with significant scale. Key benefits include:
1. Increased brand awareness for NeuroStar TMS
2. More consistent delivery of best practices
3. Enhanced benefits for all NeuroStar c...
Neuronetics: Aetna Updated Tms Coverage to Include Adolescents Aged 15 and Older With
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Neuronetics announced its participation in the 12th Annual Clinical TMS Society (CTMSS) Meeting in London from June 13-15, 2024. They will present six posters and one oral presentation showcasing data from the NeuroStar TMS System. Highlights include early prediction of nonresponse in major depressive disorder, the impact of treatment timing, efficacy of accelerated TMS protocols, effect...
NEWS
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
Neuronetics, Inc. (NASDAQ: STIM) announces significant clinical findings in Brain Stimulation journal regarding the predictive value of early symptom improvement in major depressive disorder (MDD) patients undergoing transcranial magnetic stimulation (TMS) treatment. Lack of early improvement does not predict final non-response status, emphasizing the importance of completing the full 36-...
Dow Jones· just
No comment yet